PhRMA Condemns Medicare B Rx Drug Payment Experiment
This article was originally published in Scrip
Executive Summary
The Pharmaceutical Researchers and Manufacturers of America (PhRMA) wasted no time in condemning the Obama administration's plans to launch a new experiment testing whether alternative payment designs may lead to reducing Medicare Part B expenditures, while preserving and potentially even enhancing beneficiaries' quality of care.